1002 Amylyx ALS Groups
BioCentury & Getty Images

Product Development

With patient groups’ endorsement, Amylyx, FDA to discuss approval of ALS therapy

Two foundations are calling for ‘aggressive’ approval of a third therapy for the disease

The ALS Association and I AM ALS are calling for ‘aggressive’ approval of a third therapy for the disease.

Oct 2, 2020 | 8:08 PM GMT

With two patient groups petitioning for its ALS candidate to reach patients quickly, Amylyx is preparing a pitch to FDA based on data from the 137-patient CENTAUR trial that could give the venture-backed biotech a short path to a marketed drug.

Two foundations, the ALS Association and I AM ALS, believe CENTAUR is enough. They have collected more than 43,000 signatures since launching a petition in early September calling for

Read the full 1263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE